-+ 0.00%
-+ 0.00%
-+ 0.00%
Biocon Wins EU Approval for Pertuzumab Biosimilar Pebrilzo
Share
Listen to the news
Biocon Wins EU Approval for Pertuzumab Biosimilar Pebrilzo
  • The European Commission granted marketing authorization for Biocon's Pebrilzo, a pertuzumab biosimilar, to treat HER2-positive breast cancer.
  • The drug is the first biosimilar authorized under the European Medicines Agency's new tailored clinical approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 46MHQN96P3RN4J9I) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending